research Editor's Highlights — September 2024
New therapies and treatments for hair disorders, especially in curly hair, show promise.
Search
for
Sort by
Research
30-60 / 353 results 
research current possible treatment approaches of Polycystic Ovary Syndrome (PCOS)
Different treatments for PCOS should be tailored to the individual, including lifestyle changes and various medications.
research Women With Polycystic Ovary Syndrome: A Review of Susceptibility to Type 2 Diabetes
Women with Polycystic Ovary Syndrome (PCOS) have a higher risk of developing type 2 diabetes due to insulin resistance.
research Current aspects of polycystic ovary syndrome II: treatment of hyperandrogenism, insulin resistance and infertility
Lifestyle changes, medications, and fertility treatments can improve PCOS symptoms and prevent complications.
research Alopecia and Semaglutide: Connecting the Dots for Patient Safety
Semaglutide may cause hair loss, but more research is needed to confirm this.
research Role of Sodium–Glucose Cotransporter-2 Inhibitors in Managing Polycystic Ovary Syndrome: A Systematic Review
SGLT2 inhibitors may help manage PCOS symptoms effectively.
research Dermatological adverse reactions and therapeutic potential of semaglutide, liraglutide and tirzepatide: Analysis of UK pharmacovigilance data and literature review
GLP-1 receptor agonists can help skin conditions but may cause hair loss and other skin issues.
research Semaglutide and the Skin: An Overview of Current Evidence
Semaglutide may help some skin disorders but can also cause skin issues.
research Improvement of Recalcitrant Folliculitis Decalvans With Tirzepatide: A Case Report
Tirzepatide improved symptoms and hair regrowth in a man with folliculitis decalvans.
research Antidiabetic Management Strategies for Treatment of Polycystic Ovarian Syndrome
Combining antidiabetic drugs, hormonal therapies, and lifestyle changes can improve health in women with PCOS.
research Metabolic syndrome – a new definition and management guidelines A joint position paper by the Polish Society of Hypertension, Polish Society for the Treatment of Obesity, Polish Lipid Association, Polish Association for Study of Liver, Polish Society of Family Medicine, Polish Society of Lifestyle Medicine, Division of Prevention and Epidemiology Polish Cardiac Society, “Club 30” Polish Cardiac Society, and Division of Metabolic and Bariatric Surgery Society of Polish Surgeons
The Polish medical societies have redefined metabolic syndrome and recommend lifestyle changes, certain medications, and possibly bariatric surgery for treatment. They also discuss managing related health conditions.
research Cardiovascular profile of pharmacological agents used for the management of polycystic ovary syndrome
Medications for PCOS don't seem to raise heart disease risk.
research Women with PCOS have a heightened risk of cardiometabolic and cardiovascular diseases: statement from the Experts Group on Inositol in Basic and Clinical Research and PCOS (EGOI-PCOS) and Italian Association of Hospital Cardiologists (ANMCO)
Women with PCOS have a higher risk of heart disease.
research Impact of Reducing Obesity in PCOS: Methods and Treatment Outcomes
Weight loss improves PCOS symptoms and overall health.
research Telogen Effluvium and Metabolic Stress in Modern Weight Loss Interventions: A Narrative Clinical Review
Hair loss from weight-loss treatments is usually temporary and reversible.
research INDIVIDUALIZED TREATMENT OF POLYCYSTIC OVARY SYNDROME: A MANIFESTATION-GUIDED PRACTICAL APPROACH
PCOS treatment should be personalized based on individual symptoms and health goals.
research Endocrinologia e Medicina Estética Ed. X
A comprehensive, personalized approach is needed for treating female pattern hair loss and obesity, involving multiple medical disciplines and lifestyle changes.
research Blockbuster Weight-Loss Drugs Not Tied to Suicidality, Studies Show
Weight-loss drugs are not linked to suicidal thoughts.
research Exploring the Role of GLP ‐1 Agents in Managing Diabetic Foot Ulcers: A Narrative and Systematic Review
GLP-1 receptor agonists may help manage and prevent diabetic foot ulcers.
research Semaglutide as a Cornerstone Therapy in Obesity: Clinical and Pharmacological Insights
Semaglutide is an effective weekly treatment for obesity, promoting weight loss and improving health, despite some side effects.
research Dercum Disease: Exploratory Therapeutic Approaches in the Absence of Standardized Medical Treatment—A Single Center Case Series
Individualized treatments may help manage Dercum's disease symptoms.
research Dermatologic Implications of Glycemic Control Medications for Patients with Type 2 Diabetes Mellitus
Glycemic control medications for Type 2 diabetes can affect skin conditions like psoriasis.
research Metabolic syndrome — a new definition and management guidelines
New guidelines stress early diagnosis and lifestyle changes to manage metabolic syndrome and prevent complications.
research Farmácia Avenida Brasil, Porto
Community pharmacies and pharmacists play a crucial role in improving community health.
research Computational Drug Repositioning in Cardiorenal Disease: Opportunities, Challenges, and Approaches
Drug repositioning is a promising way to quickly develop new treatments, especially for rare diseases.
research A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome
Liraglutide caused significant weight loss in some obese women with PCOS, especially those with severe obesity and insulin resistance.
research GLP-1 Receptor Analogs: Evidence Linking to Effect on Metabolic and Reproductive Functions in Patients with PCOS and Obesity
GLP-1 receptor analogs may help improve metabolism and reproductive health in people with PCOS and obesity.
research Farmácia da Boa Hora, Porto e nos Serviços Farmacêuticos do Hospital Lusíadas, Porto
Tailored medication preparation and ongoing education are crucial for effective treatments.
research Non-clinical safety evaluation and risk assessment to human of aleglitazar, a dual PPAR α/γ agonist, and its major human metabolite
Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.
research Acquired Alopecias in Mexican Adults: A Clinical and Epidemiological Study of 1,888 Patients
Understanding alopecia in Mexican adults helps create better, tailored treatments.